Cargando…

Exploiting the relevance of CA 19-9 in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most common cause of cancer-related deaths in the United States. It has a poor prognosis and remains a difficulty to treat malignancy. Over the past several decades, significant efforts have been directed towards developing new approach...

Descripción completa

Detalles Bibliográficos
Autores principales: Salleh, Syaza, Thyagarajan, Anita, Sahu, Ravi P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566512/
https://www.ncbi.nlm.nih.gov/pubmed/37822969
http://dx.doi.org/10.20517/2394-4722.2020.70
_version_ 1785118927824617472
author Salleh, Syaza
Thyagarajan, Anita
Sahu, Ravi P.
author_facet Salleh, Syaza
Thyagarajan, Anita
Sahu, Ravi P.
author_sort Salleh, Syaza
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most common cause of cancer-related deaths in the United States. It has a poor prognosis and remains a difficulty to treat malignancy. Over the past several decades, significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment. In recent years, the measurement of serum carbohydrate antigen 19-9 (CA 19-9) has become one of the most validated and extensively used tumour biomarkers for PDAC. In particular, serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment. However, despite its clinical relevance, the implications on diagnosis or accurately predicting tumour resectability, and monitoring disease symptoms in PDAC patients remains limited. This current review highlights the recent updates on the applicability of CA 19-9, its exploitation, and challenges in predicting the treatment efficacy and responses in PDAC patients.
format Online
Article
Text
id pubmed-10566512
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-105665122023-10-11 Exploiting the relevance of CA 19-9 in pancreatic cancer Salleh, Syaza Thyagarajan, Anita Sahu, Ravi P. J Cancer Metastasis Treat Article Pancreatic ductal adenocarcinoma (PDAC) is currently the fourth most common cause of cancer-related deaths in the United States. It has a poor prognosis and remains a difficulty to treat malignancy. Over the past several decades, significant efforts have been directed towards developing new approaches to enhance the efficacy of therapeutic regimens for PDAC treatment. In recent years, the measurement of serum carbohydrate antigen 19-9 (CA 19-9) has become one of the most validated and extensively used tumour biomarkers for PDAC. In particular, serum CA 19-9 levels have been explored as a validated tool to predict either the signs of disease progression or the response to treatment. However, despite its clinical relevance, the implications on diagnosis or accurately predicting tumour resectability, and monitoring disease symptoms in PDAC patients remains limited. This current review highlights the recent updates on the applicability of CA 19-9, its exploitation, and challenges in predicting the treatment efficacy and responses in PDAC patients. 2020 2020-09-17 /pmc/articles/PMC10566512/ /pubmed/37822969 http://dx.doi.org/10.20517/2394-4722.2020.70 Text en https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Salleh, Syaza
Thyagarajan, Anita
Sahu, Ravi P.
Exploiting the relevance of CA 19-9 in pancreatic cancer
title Exploiting the relevance of CA 19-9 in pancreatic cancer
title_full Exploiting the relevance of CA 19-9 in pancreatic cancer
title_fullStr Exploiting the relevance of CA 19-9 in pancreatic cancer
title_full_unstemmed Exploiting the relevance of CA 19-9 in pancreatic cancer
title_short Exploiting the relevance of CA 19-9 in pancreatic cancer
title_sort exploiting the relevance of ca 19-9 in pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566512/
https://www.ncbi.nlm.nih.gov/pubmed/37822969
http://dx.doi.org/10.20517/2394-4722.2020.70
work_keys_str_mv AT sallehsyaza exploitingtherelevanceofca199inpancreaticcancer
AT thyagarajananita exploitingtherelevanceofca199inpancreaticcancer
AT sahuravip exploitingtherelevanceofca199inpancreaticcancer